Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581711 | 0.85 | SMN1; SMN2 (0.56) | NAMPTTSHRLMNAHTTSMN1; SMN2 | |
| SCHEMBL1581938 | 0.82 | NAMPT (0.42) | NAMPTJAK1TSHRLMNAHTT | |
| SCHEMBL1582101 | 0.74 | GCK (0.35) | ALDH1A1 | |
| SCHEMBL1581694 | 0.74 | GCK (0.67) | NAMPTJAK1TSHRLMNAHTT | |
| SCHEMBL13757062 | 0.74 | GCK (0.67) | NAMPTJAK1TSHRLMNAHTT | |
| SCHEMBL1581903 | 0.74 | GCK (0.47) | SMN1; SMN2 | |
| SCHEMBL1581684 | 0.73 | HTR7 (0.37) | LMNAHTTALDH1A1PKM | |
| SCHEMBL1581696 | 0.73 | GCK (0.50) | NAMPTJAK1SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL13757061 | 0.73 | GCK (0.50) | NAMPTJAK1SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL1582098 | 0.71 | GCK (0.36) | TSHRHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585739-B1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | LILLY CO ELI (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7576108-B2 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1585739-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063179-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | GCK, GCKR, GALK1 | NAMPT 635/4885JAK1 4450/4885TSHR 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.